Dublin, Oct. 13, 2017 (GLOBE NEWSWIRE) -- The "Molecular Cytogenetics Market - Global Opportunity Analysis and Industry Forecasts to 2022" report has been added to Research and Markets' offering.
Global molecular cytogenetics market is expected to reach USD 2,266.4 million by 2022, supported by a CAGR of 11% during the forecast period of 2017 to 2022
The global molecular cytogenetics market is mainly driven by increasing focus on preventive healthcare measures, increasing genetic abnormalities, rising aging population and subsequent increase in various chronic diseases, growing need to reduce mounting healthcare cost, and increasing focus on clinical and research diagnosis.
Moreover, increasing focus on targeted based therapies and growing predictive and presymptomatic genetic testing further provides significant opportunities in this market. However, lack of awareness about emerging diagnosis technologies, high cost of diagnosis, unfavourable reimbursement scenario, and technical limitations and complexities of the equipment inhibits the growth of the market to some extent. The global molecular cytogenetics market is mainly segmented by technique (fluorescence in situ hybridization, comparative genomic hybridization, in situ hybridization, karyotyping, and banding techniques), by product (instruments, kits and reagents, software, services, and consumable/accessories ), by application (oncology, genetic disorders, personalized medicines, and other), and by end user (pharmaceuticals and biotechnological companies, clinical and diagnostic laboratories, and academic institutes). The large share of this region is primarily attributed to the increased funding in medical research, stringent drug development regulations which demand molecular cytogenetics techniques, growing aging population and thereby prevalence of various chronic diseases, and direct & indirect financial investments in the pharma biotech companies. However, Asia-Pacific region possesses lucrative growth potential for the molecular cytogenetic market during the forecast period owing to the increasing demand in China and India, growing population, various technological advancements, growing investment from government & non-government bodies, and growing pharma biotech industry in the region. Scope of the Report Market by Technique:
- Fluorescence In Situ Hybridization
- Comparative Genomic Hybridization
- Chromosomal CGH
- Array CGH
- In Situ Hybridization
- Karyotyping
- Spectral Karyotyping
- Virtual Karyotyping
- Banding Techniques
- G banding
- Q banding
- R banding
- C banding
- T banding
Market by Product:
- Instruments
- Systems
- Imager and Scanners
- Kits and Regents
- Reagents
- Testing kits
- Probes
- Software
- Services
- Consumables/Accessories
Market by Application:
- Oncology
- Genetic Disorders
- Personalized Medicines
- Others
Market by End-user:
- Pharmaceutical and Biotechnology Companies
- Clinical and Diagnostic Companies
- Academic Institutes
- Others
Key Topics Covered:
1. Introduction 1.1. Market Ecosystem 1.2. Currency And Limitations 1.2.1. Currency 1.2.2. Limitations 1.3. Key Stakeholders 2. Research Methodology 2.1. Research Process 2.1.1. Secondary Research 2.1.2. Primary Research 2.1.3. Market Size Estimation 3. Executive Summary 4. Market Insights 4.1. Introduction 4.2 Drivers 4.2.1. Increasing Focus on Preventive Healthcare Measures 4.2.2. Increasing Genetic Abnormalities 4.2.3. Increasing Aging Population and Subsequent Increase in the Various Chronic Diseases 4.2.4. Growing Need to Reduce Mounting Healthcare Cost 4.2.5. Increasing Focus on Research and Clinical Diagnosis 4.3. Restraints 4.3.1. Lack Of Awareness About Emerging Diagnosis Technologies 4.3.2. High Cost of Diagnosis 4.3.3. Unfavourable Reimbursement Scenario 4.3.4. Technical Limitations and Complexities of The Equipment 4.4. Opportunities 4.4.1. Emerging Economies: China, India, South Korea, and Southeast Asia 4.4.2. Increasing Focus on Targeted Based Therapies 4.4.3. Increase in Predictive and Presymptomatic Genetic Testing 4.5. Trends 4.5.1. Transition From Fluorescence In Situ Hybridization To Array Based Techniques 5. Molecular Cytogenetics Market, by Technique 5.1. Introduction 5.2. Fluorescence In Situ Hybridization 5.3. In Situ Hybridization 5.4. Comparative Genomic Hybridization 5.4.1. Chromosomal-Comparative Genomic Hybridization 5.4.2. Array-Comparative Genomic Hybridization 5.5. Karyotyping 5.5.1. Spectral Karyotyping 5.5.2. Virtual Karyotyping 5.6. Banding Techniques 5.6.1. G Banding 5.6.2. Q Banding 5.6.3. R Banding 5.6.4. C Banding 5.6.5. T Banding 6. Molecular Cytogenetics Market, by Product 6.1. Introduction 6.2. Instruments 6.2.1. Systems 6.2.2. Imagers and Scanners 6.3. Kits and Reagents 6.3.1. Testing Kits 6.3.2. Probes 6.3.3. Reagents 6.4. Software 6.5. Services 6.6. Consumables/Accessories 7. Molecular Cytogenetics Market, b y Application 7.1. Introduction 7.2 Oncology 7.3 Genetic Disorders 7.4 Personalized Medicines 7.5 Other Applications 8. Molecular Cytogenetics Market, by End-User 8.1. Introduction 8.2. Pharmaceutical and Biotechnology Companies 8.3. Clinical and Diagnostic Laboratories 8.4. Academic Institutes 8.5. Others 9. Molecular Cytogenetics Market, by Geography 10. Competitive Landscape 10.1. Introduction 10.2. New Product Launches & Enhancements 10.3. Acquisitions & Mergers 10.4. Expansions 10.5. Agreements, Collaborations, and Partnerships 11. Company Profiles 11.1. Thermo Fisher Scientific 11.2. Abbott Laboratories 11.3. Agilent Technologies 11.4. Perkinelmer 11.5. Bio-Rad Laboratories, Inc. 11.6. Applied Spectral Imaging, Inc. 11.7. Quest Diagnostics 11.8. Roche Holding AG 11.9. Danaher Corporation 11.10. Illumina, Inc. 11.11. Oxford Gene Technology 11.12 Others 12. Appendix
For more information about this report visit https://www.researchandmarkets.com/research/bhmbwf/molecular
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Genomics
